| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.9 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |